Conatus Pharmaceuticals Inc (CNAT) Expected to Announce Quarterly Sales of $8.51 Million

Analysts expect that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will report $8.51 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Conatus Pharmaceuticals’ earnings, with the highest sales estimate coming in at $10.00 million and the lowest estimate coming in at $6.13 million. Conatus Pharmaceuticals posted sales of $8.80 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 3.3%. The firm is expected to announce its next earnings report on Wednesday, March 6th.

According to Zacks, analysts expect that Conatus Pharmaceuticals will report full year sales of $34.81 million for the current fiscal year, with estimates ranging from $32.30 million to $36.18 million. For the next fiscal year, analysts expect that the business will post sales of $46.87 million, with estimates ranging from $25.32 million to $80.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Conatus Pharmaceuticals.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its earnings results on Thursday, November 1st. The biotechnology company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). The company had revenue of $7.67 million for the quarter, compared to analysts’ expectations of $9.70 million. Conatus Pharmaceuticals had a negative return on equity of 83.99% and a negative net margin of 52.77%.

CNAT has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating on shares of Conatus Pharmaceuticals in a report on Monday. Oppenheimer set a $14.00 price target on Conatus Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 2nd. Finally, ValuEngine upgraded Conatus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, September 22nd. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Conatus Pharmaceuticals has an average rating of “Buy” and a consensus target price of $11.80.

Conatus Pharmaceuticals stock traded down $0.41 during mid-day trading on Tuesday, hitting $5.32. The stock had a trading volume of 15,019 shares, compared to its average volume of 623,252. The stock has a market cap of $156.76 million, a price-to-earnings ratio of -8.69 and a beta of 1.84. Conatus Pharmaceuticals has a 12 month low of $3.22 and a 12 month high of $7.95. The company has a quick ratio of 2.39, a current ratio of 2.39 and a debt-to-equity ratio of 0.83.

A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. boosted its holdings in Conatus Pharmaceuticals by 45.4% during the first quarter. BlackRock Inc. now owns 2,316,808 shares of the biotechnology company’s stock worth $13,601,000 after buying an additional 723,413 shares during the last quarter. Alambic Investment Management L.P. boosted its holdings in Conatus Pharmaceuticals by 207.0% during the second quarter. Alambic Investment Management L.P. now owns 264,665 shares of the biotechnology company’s stock worth $1,133,000 after buying an additional 178,461 shares during the last quarter. Bank of America Corp DE boosted its holdings in Conatus Pharmaceuticals by 75.7% during the second quarter. Bank of America Corp DE now owns 140,687 shares of the biotechnology company’s stock worth $602,000 after buying an additional 60,604 shares during the last quarter. Paloma Partners Management Co bought a new position in Conatus Pharmaceuticals during the second quarter worth about $547,000. Finally, JPMorgan Chase & Co. raised its position in shares of Conatus Pharmaceuticals by 1,205.7% during the first quarter. JPMorgan Chase & Co. now owns 74,062 shares of the biotechnology company’s stock worth $435,000 after purchasing an additional 68,390 shares during the period. Hedge funds and other institutional investors own 33.47% of the company’s stock.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Featured Article: Bond

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply